Treatment of growth hormone attenuates hepatic steatosis in hyperlipidemic mice via downregulation of hepatic CD36 expression

• Published in: Animal cells and systems Vol. 24; no. 3; pp. 151 - 159
• Main Authors: Jang, Hyung Seok, Kim, Kyeongdae, Lee, Mi-Ran, Kim, Shin-Hye, Choi, Jae-Hoon, Park, Mi Jung
• Format: Journal Article
• Language: English
• Published: England Taylor & Francis 03.05.2020; Taylor & Francis Ltd; Taylor & Francis Group; 한국통합생물학회
• Subjects: Adipose tissue; Arteriosclerosis; Atherosclerosis; Attenuation; Bioaccumulation; blood lipids; Body weight; CD36; CD36 antigen; Collagen; Developmental Biology; Fatty liver; Gene expression; Growth hormone; Growth hormones; hepatic steatosis; hyperlipidemia; IL-1β; inflammation; Insulin-like growth factor I; Lesions; Lipid metabolism; Lipids; Liver diseases; low density lipoprotein; Low density lipoprotein receptors; Macrophages; Metabolic disorders; Metabolism; mRNA; Muscles; Nutrient deficiency; obesity; Physical growth; Physiological effects; Receptor density; Smooth muscle; somatotropin; Steatosis; therapeutics; 생물학; atherosclerosis; hyperlipidemia; CD36; Growth hormone; hepatic steatosis
• ISSN: 1976-8354; 2151-2485; 2151-2485
• DOI: 10.1080/19768354.2020.1778080

The recombinant human growth hormone (GH) has been used for the treatment of growth hormone deficiency (GHD) and diverse short stature state, and its physiological and therapeutic effects are well documented. However, since the effect of GH treatment on metabolic disorders has not been well characterized, we injected GH to Western diet-fed low-density lipoprotein receptor-deficient (Ldlr −/− ) mice to understand the exact effect of GH on metabolic diseases including atherosclerosis, hepatic steatosis, and obesity. Exogenous GH treatment increased plasma IGF-1 concentration and decreased body weight without affecting serum lipid profiles. GH treatment changed neither atherosclerotic lesion size nor collagen and smooth muscle cells accumulation in the lesion. GH treatment reduced macrophage accumulation in adipose tissue. Importantly, GH treatment attenuated hepatic steatosis and inflammation. The hepatic expression IL-1β mRNA were decreased by GH treatment. The mRNA and protein levels of CD36 were markedly decreased in GH treated mice without significant changes in other molecules related to lipid metabolism. Therefore, the treatment of GH treatment could attenuate hepatic steatosis and inflammation with downregulation of CD36 expression in hyperlipidemic condition.